Connect with us
  • Elysium

Stroke

Clot-busting drug could improve stroke treatment

Published

on

A novel ‘clot-busting’ drug is able to effectively restore blood flow in the brains of mice, opening the door for a safer and more effective stroke treatment.

The compound – an enzyme called caADAMTS13 – could dissolve clots in patients that are resistant to current treatment, the study from the University of Manchester has revealed. 

tPA – currently used by doctors in the acute phase of a stroke – works for many patients, however, it is not able to break down clots which are rich in Von Willebrand Factor (VWF), a large string shaped protein molecule which plays a crucial role in clot formation.

Around 50 per cent of all clots are rich in VWF – which tethers circulating clotting cells called platelets at sites of clot formation – and are resistant to tPA.

The team examined the efficacy of the drug in mice and compared it with the wildtype variant of the enzyme – called wtADAMTS13 that occurs naturally in the body.

When given one hour after a stroke, the new drug significantly reduced VWF by dismantling its long chains – five times more quickly than the wildtype variant achieved.

The drug also prevented a type of white blood cell called a neutrophil from entering the brain tissue starved of blood supply and thought to be a cause of the damage to brain cells.

Stroke is caused by a reduction in blood flow to the brain, which most frequently results in loss of movement, problems with speech and other symptoms in the patient.

The reduced blood flow is most often caused by a blood clot that lodges in the narrow blood vessels that supply the brain, which means the cells of the brain don’t get the energy they need to work.

If blood flow is not quickly restored the brain cells will die leading to permanent brain damage and, if severe, death.

Now, through the study of the novel compound – which is patented by the team and funded by the British Heart Foundation – stroke survivors can have fresh hope of recovery. 

Professor Stuart Allan from the University of Manchester, co-author of the study and co-director of the Geoffrey Jefferson Brain Research Centre, said: “Our novel drug is able break down the blood clots that are resistant to the current treatment tPA. In doing so, more stroke patients could show recovery of function than at present.

“Clearly there is still some way to go, and we need to know if the drug is effective a period of time after the stroke has occurred – with less risk of haemorrhage.

”We are optimistic that we will be able to show this drug can to do that; once we have, we hope to move onto human trials. It’s very exciting.”

Professor Metin Avkiran, associate medical director at the British Heart Foundation, said: “The majority of strokes, which can have such devastating consequences, are caused by a blood clot cutting off blood supply to part of the brain.

“With over 100,000 strokes in the UK each year, new treatments are sorely needed to improve outcomes for patients. 

“These promising findings suggest that drugs that target Von Willebrand Factor (VWF) have the potential to safely and effectively dissolve blood clots that resist currently available therapies.

“More research will be needed to understand whether these results in mice can be replicated in humans, and whether this can help to improve survival and recovery for stroke patients.”

Tech

GripAble praised by MP

Stephen Hammond MP hails its innovation and “extraordinary” success to date and potential

Published

on

The progress of GripAble has been hailed as “extraordinary” by its local MP, who praised its innovation and ongoing progress in transforming neurorehab and wider healthcare.

GripAble, the UK technology company digitising upper limb rehabilitation from hospital to home, welcomed Stephen Hammond, MP for Wimbledon, to its international sales and distribution centre.

Mr Hammond visited GripAble’s office in Wimbledon to learn how private equity investment has helped it to scale its industry-leading data platform and therapy services and expand GripAble into Europe and the US, as well as how an international company has successfully stemmed from the local business community. 

During his visit, the MP met the GripAble team and listened to a presentation by GripAble co-founder and CEO Dr Paul Rinne, who shared the background to GripAble and its growth story to date, as well as plans and ambitions for the future.

Prior to becoming an MP, Stephen Hammond worked for a leading fund management company and multiple investment banks, so was particularly interested in the funding GripAble has received to date, including the recent close of its $11m funding round. 

With more than 8,000 individuals having already used the platform, GripAble has established itself as a leading technology in the remote-rehab space in the UK, recording 100,000 activity sessions and 27 million movement repetitions across its users.

Stephen Hammond MP said: “GripAble proves that innovative companies of the future that are building products that will transform healthcare can be based anywhere, but I’m particularly proud that GripAble has started out in Wimbledon. 

“It’s been wonderful to see the development of the company over the last two years since first meeting Paul, and I’m sure the developments over the next three years will be equally extraordinary, particularly with the backing of private equity investment.”

Dr Rinne said: “Today’s visit was a fantastic opportunity for us to showcase GripAble’s story and vision to a Member of Parliament and explain how private equity investment can help UK-based entrepreneurs take ideas from seed stage through to global scaling, and compete on the international stage. 

“The investment we have received will accelerate GripAble’s journey to delivering end-to-end patient rehabilitation and connecting millions to their own personal home-based clinic. 

“With the backing of investors such as IP Group and Parkwalk, we will benefit from a wealth of insight and experience that will support us in growing our platform in the US and expanding our clinical and commercial evidence base. 

“It is great to be able to work with such supportive investors that make our lives so much easier.”

Continue Reading

Stroke

True impact of stroke underestimated, new research reveals

The Stroke Association study shows the lack of knowledge of the levels of disability it can cause, or that it is the UK’s fourth biggest killer

Published

on

More than half of people in the UK do not know stroke is the fourth biggest killer in Britain, with a fifth of people underestimating its impact, new research has revealed.

A new study from the Stroke Association reveals 51 per cent did not realise how deadly stroke can be, and 18 per cent did not know it is the UK’s fifth biggest cause of disability. 

In fact, two thirds of the 1.3million stroke survivors in the UK find themselves living with a disability, with over 50 per cent dependent on others for every day activities. 

The research also found that people do not understand the true long term damage a stroke can cause:

  • More than two-thirds (67 per cent) of people are unaware that fatigue is a common hidden effect of stroke
  • More than two thirds (67 per cent) don’t realise that stroke can cause depression and anxiety
  • Around a third of people (32 per cent) don’t know that communication difficulties are common after stroke
  • Almost three quarters of people (74 per cent) don’t know that stroke can affect hearing
  • Two thirds (66 per cent) are unaware that stroke survivors can experience vision problems.

Despite the devastating impact of stroke, stroke research remains underfunded and receives far less funding than other health conditions that have similar life-long effects.

For personal trainer Glen Eastick, his stroke happened when he was just 33 and a new father in July 2020, during the pandemic period when hospital visits for stroke decreased significantly.

Glen’s symptoms started while he was preparing his lunch. 

“I briefly lost the use of my arm for about ten seconds and dribbled a bit but then continued making lunch,” said Glen.

“Then when I went into my next online session I realised I couldn’t talk. Nothing was coming out except the odd word. My client was saying ‘Are you ok?’

“My girlfriend Bex was out on a walk with our six-week-old baby Evie and as soon as she came back she realised something was wrong as I was struggling to talk. She called the ambulance and I was rushed into hospital.”

Ironically, the stroke specialty doctor waiting to treat Glen at the Queen Alexandra Hospital in Portsmouth, was James Beckett who is also one of his personal fitness clients.

A scan confirmed that Glen had had a stroke and he was thrombolysed – given special drugs to dissolve the clot which was blocking the blood supply and killing cells in his brain.

Thanks to the prompt action by Bex who spotted the “FAST” stroke symptoms, the skills of hospital staff and his own determination, Glen has made a good recovery.

Now Glen is backing the Stroke Association’s call for more research into stroke.

Juliet Bouverie, chief executive of the Stroke Association, said: “Stroke strikes every five minutes in the UK and while it changes lives in an instant, the brain can adapt and rebuild after stroke. 

“That’s why research means everything to our nation’s 1.3 million stroke survivors and their families, because of the life-changing impact it could have on their future.

“Our pioneering research has been at the centre of major breakthroughs that have saved lives and sparked innovation in stroke care and treatment. 

“From laying the foundations for the Act FAST campaign, one of the most successful public health awareness campaigns in England, to funding early research into the emergency stroke treatment thrombectomy, many patients have been spared the most devastating effects of stroke as a result of our research.

“Despite stroke still being the fourth biggest killer in the UK, research has helped to more than halve the rate of deaths from stroke over the last three decades. It’s absolutely crucial that we continue this progress, but we can’t do this without vital funding.”

Continue Reading

Stroke

Online intervention ‘can improve stroke survivors’ quality of life’

Accessible, interactive and tailored support can deliver significant health benefits, a new study reveals

Published

on

Online support for adult stroke survivors that provides accessible, interactive and tailored interventions is associated with better health-related quality of life, new research has revealed. 

Stroke can lead to serious physical and cognitive disability, with lifestyle and health behaviours including smoking and drinking, physical activity, diet and depression all being important in survivors’ quality of life. 

Now, a new study has revealed that online programmes which support stroke survivors with such factors can deliver great benefits. 

It builds further on existing research into other forms of remote rehab to show how impactful online and virtual support can be. 

“Online platforms are a viable and impactful model to address the health information needs and behaviour change challenges of stroke survivors,” says Dr Ashleigh Guillaumier, from the University of Newcastle.

Led by Dr Guillaumier, and senior author Professor Billie Bonevski from Flinders University, the study undertook a randomised control trial to evaluate the online program Prevent 2nd Stroke” (P2S), which encourages users to set goals and monitor progress across various health risk areas.

399 adult stroke survivors with an average age of 66 were asked to complete a telephone survey, following which they were randomly assigned to receive either a list of generic health information websites or 12 weeks of access to the P2S online program. 

The group with P2S access also received additional text messages encouraging use of the program.

Nearly all participants then completed a six month follow-up survey, with the researchers finding those who received P2S access had a higher health-related quality of life (HRQOL) score than those who received the generic health information.

Compared to those in the control group, significantly higher proportions of people in the group who received access to P2S also reported having no problems with personal care and an ability to participate in their usual daily activities.

The authors say that while most of the participants were generally “well” stroke survivors, with little to no disability, limiting the scope of the study, it still points to the benefits of the online program.

“This paper is the culmination of eight years of research, starting with a small grant from the National Stroke Foundation that funded the development of the online program which was co-developed with consumers and key stakeholders,” added Professor Bonevski.

“The next step for Prevent Second Stroke is to scale up its implementation to ensure it reaches and benefits the highest number of people who have experienced a stroke, including those with greater stroke-related disability.”

Continue Reading

Newsletter

Sign up for the NR Times newsletter
I would like to receive by email other offers, promotions and services from Aspect Publishing Ltd and its group companies.*

Trending